Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Short-Timer Whitehouse Has His Say
"While Sen. Sheldon Whitehouse (D-R.I.) is expected to be on the Senate Health, Education, Labor and Pensions Committee only for a short time, he should have a major effect on health reform," Roll Call reports. "Senate Majority Leader Harry Reid (D-Nev.) chose Whitehouse to temporarily take the place of former Sen. Hillary Rodham Clinton (D-N.Y.), now secretary of State, on HELP because of his experience with health care policy at the state level." But when Sen. Al Franken, D-Minn., takes over "the long-vacant Minnesota seat, Whitehouse"s time on the committee will soon be coming to an end -- but not before the health debate is finished."
generic viagra online
96-Week Safety And Efficacy Findings Presented For INTELENCE(TM) (etravirine) As Part Of HIV Combination Therapy
Ninety-six week pooled results from two Phase 3 studies (DUET-1 and DUET-2) showed that significantly more treatment-experienced HIV-1-infected adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) resistance had an undetectable viral load (DUET-1 and -2 Study Design
News of the day
Medimix International To Exhibit At American Society of Clinical Oncology AGM
Medimix International, a leader in global healthcare marketing research for life sciences industry, announced that it will be exhibiting at the 45th AGM of the American Society of Clinical Oncology, which will take place in Orlando, Florida from May 29-June 2, 2009. The annual ASCO meeting is considered to be the premier educational and scientific event in the oncology community, a forum for cutting-edge scientific and educational developments in oncology with a focus on personalizing cancer care.
Nutrition

NanoViricides, Inc. Eye Drug Testing Has Begun

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that testing of its topical eye drops drug candidate has begun at two different, independent facilities. Testing of this broad-spectrum, topical, eye drug candidate by a major pharmaceutical company ("Party") is now in progress. The Company had previously announced in March that it had signed a Material Transfer Agreement with this Party. In addition, the Company is also evaluating this drug candidate against herpes keratitis of the eye at Thevac, LLC, a spin-off of the Louisiana State University (Study Director, K. G. Kousoulas, PhD). The testing at the two facilities will independently evaluate performance of this drug candidate against several types and strains of many different viruses that cause keratitis or conjunctivitis of the eye. Cell culture studies as well as animal studies with different animal models have been planned. "Execution of the material transfer agreement (MTA) is a step towards a potential licensing agreement," said Eugene Seymour, MD, MPH, CEO of Nanoviricides, Inc. The terms of the agreement do not allow the disclosure of the identity of the Party or the exact terms of the MTA. HSV and some adenoviruses cause most of the cases of keratitis, a serious infection of the cornea. Importantly, HSV infection can lead to corneal scarring that may necessitate corneal transplantation. In addition, some adenoviruses cause a majority of conjunctivitis cases ("pink eye"). The remaining cases of conjunctivitis, caused by bacteria, are treatable with topical antibiotics. Currently, there are no effective treatments for viral diseases of the exterior portion of the eye. The Company has already demonstrated strong efficacy against an adenovirus-caused external eye disease called epidemic kerato-conjunctivitis (EKC). Rapid clinical improvement in the treated animals was reported by independent researchers who tested the effects of the nanoviricides drug candidate against adenoviral EKC. Based on computer modeling, the Company believes that the broad-spectrum nature of the ligand used in this nanoviricide should enable it to be effective against HSV. The total market for all forms of viral conjunctivitis/keratitis is estimated to be in the billions of dollars. The incidence of severe herpes (HSV) keratitis is estimated to be 250,000 cases per year in the USA. In Japan, where EKC is a reportable disease, it is estimated that there are at least one million cases per year. The number of cases of non-specific conjunctivitis (pink eye) is considered to be far greater, possibly into tens of millions in the US, and into hundreds of millions worldwide. NanoViricides


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009